Laguna

Laguna engineers live microbial therapies that deliver a precisely tuned combination of immune-activating signals that conventional therapies cannot achieve. Unlike antibodies that target a single checkpoint or CAR-T that requires costly manufacturing, Laguna's platform activates the innate immune system, like γδ T cells, to generate a durable, broad anti-tumor response. This approach is off-the-shelf, manufacturable at low cost, and applicable across multiple tumor types. Our lead program in AML is entering Phase 1 in 2026 with FDA clearance already in hand.

Laguna has raised ~$10M in a priced Seed round from Pac8, SOSV, TVC, and others, which will fund the company through meaningful patient data in their company-sponsored Phase 1 study in AML, which will begin enrolling in Q3 2026. Laguna is raising a $3-5M convertible note (40% committed) to fund clinical expansion into additional indications. This capital is designed to generate significant and additional de-risking clinical data that positions the company for a Series A or strategic partnership at significantly improved terms. Comparable acquisitions include Ipsen/ImCheck ($1.0B, Oct '25), Amgen/Dark Blue ($840M, Jan '26), and BI/T3 Pharma ($500M, Nov '23).